Cabot Corporation $CBT Stake Lessened by Paradiem LLC

Paradiem LLC trimmed its stake in shares of Cabot Corporation (NYSE:CBT) by 20.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 118,851 shares of the specialty chemicals company’s stock after selling 30,246 shares during the quarter. Cabot makes up 1.9% of Paradiem LLC’s portfolio, making the stock its 24th biggest position. Paradiem LLC owned 0.22% of Cabot worth $7,877,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. NewEdge Advisors LLC grew its stake in Cabot by 2,559.5% in the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock worth $82,000 after purchasing an additional 947 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Cabot by 32.5% in the first quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after purchasing an additional 108,645 shares during the period. Empowered Funds LLC boosted its holdings in shares of Cabot by 102.6% in the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after buying an additional 14,260 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Cabot by 3.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after acquiring an additional 4,048 shares during the period. Finally, Geneos Wealth Management Inc. grew its holdings in shares of Cabot by 409.0% during the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 364 shares during the last quarter. Institutional investors own 93.18% of the company’s stock.

Wall Street Analysts Forecast Growth

CBT has been the topic of a number of research reports. Zacks Research upgraded Cabot from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 27th. Mizuho set a $75.00 target price on Cabot and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. UBS Group upped their price target on shares of Cabot from $74.00 to $81.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Cabot in a research report on Monday, December 29th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $85.00 target price on shares of Cabot in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $73.75.

Cabot Trading Up 1.2%

Shares of Cabot stock opened at $68.75 on Friday. The business has a fifty day simple moving average of $72.98 and a 200-day simple moving average of $70.72. Cabot Corporation has a fifty-two week low of $58.33 and a fifty-two week high of $84.54. The firm has a market cap of $3.59 billion, a price-to-earnings ratio of 12.04, a price-to-earnings-growth ratio of 8.96 and a beta of 0.86. The company has a quick ratio of 1.09, a current ratio of 1.67 and a debt-to-equity ratio of 0.49.

Cabot (NYSE:CBT) last issued its quarterly earnings results on Tuesday, February 3rd. The specialty chemicals company reported $1.53 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.13. The company had revenue of $849.00 million during the quarter, compared to the consensus estimate of $889.11 million. Cabot had a net margin of 8.62% and a return on equity of 22.82%. Cabot’s revenue was down 11.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.76 EPS. Cabot has set its FY 2026 guidance at 6.000-6.500 EPS. On average, equities analysts forecast that Cabot Corporation will post 7.57 EPS for the current fiscal year.

Cabot Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 13th. Shareholders of record on Friday, February 27th were given a $0.45 dividend. The ex-dividend date was Friday, February 27th. This represents a $1.80 annualized dividend and a yield of 2.6%. Cabot’s payout ratio is 31.52%.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.